- Home
- NVRI vs OLMA Comparison
NVRI vs OLMA Comparison
Compare NVRI & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVRI
- OLMA
- Stock Information
- Founded
- NVRI 1853
- OLMA 2006
- Country
- NVRI United States
- OLMA United States
- Employees
- NVRI N/A
- OLMA N/A
- Industry
- NVRI Diversified Commercial Services
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- NVRI Miscellaneous
- OLMA Health Care
- Exchange
- NVRI Nasdaq
- OLMA Nasdaq
- Market Cap
- NVRI 572.2M
- OLMA 465.4M
- IPO Year
- NVRI N/A
- OLMA 2020
- Fundamental
- Price
- NVRI $7.65
- OLMA $6.10
- Analyst Decision
- NVRI Hold
- OLMA Strong Buy
- Analyst Count
- NVRI 1
- OLMA 5
- Target Price
- NVRI $10.00
- OLMA $26.25
- AVG Volume (30 Days)
- NVRI 998.5K
- OLMA 1.2M
- Earning Date
- NVRI 10-31-2024
- OLMA 11-12-2024
- Dividend Yield
- NVRI N/A
- OLMA N/A
- EPS Growth
- NVRI N/A
- OLMA N/A
- EPS
- NVRI N/A
- OLMA N/A
- Revenue
- NVRI $2,086,473,000.00
- OLMA N/A
- Revenue This Year
- NVRI $16.52
- OLMA N/A
- Revenue Next Year
- NVRI $0.21
- OLMA N/A
- P/E Ratio
- NVRI N/A
- OLMA N/A
- Revenue Growth
- NVRI N/A
- OLMA N/A
- 52 Week Low
- NVRI $6.57
- OLMA $5.56
- 52 Week High
- NVRI $12.79
- OLMA $16.78
- Technical
- Relative Strength Index (RSI)
- NVRI 50.28
- OLMA 27.05
- Support Level
- NVRI $7.55
- OLMA $5.56
- Resistance Level
- NVRI $7.83
- OLMA $6.87
- Average True Range (ATR)
- NVRI 0.27
- OLMA 0.81
- MACD
- NVRI 0.05
- OLMA -0.28
- Stochastic Oscillator
- NVRI 65.83
- OLMA 10.12
About NVRI Enviri Corporation
Enviri Corp engages in providing a broad range of environmental services and related solutions. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company serves a diverse customer base by offering critical recycle and reuse solutions for their waste streams, enabling customers to address their complex environmental challenges.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.